
Allo CAR T Myeloma Therapies with Jesus Berdeja, MD, Sarah Cannon Research Institute
TO JOIN THE SHOW BY PHONE, PLEASE CALL (347) 637-2631
CAR T therapies are expanding as multiple myeloma treatment options. In addition to the two currently FDA approved CAR T therapies (Abecma and Carvykti) which use a patient's own T cells in a production process, new allo (off-the-shelf) options are being developed in clinical trials. Dr. Jesus Berdeja is one of the leading CAR T experts in multiple myeloma and in this episode, he will share the current development taking place for allo CAR T therapies. Join us to learn more about this exciting field in myeloma research which may provide faster and more available treatment options for patients.
Thanks to our episode sponsor

Note: Myeloma Crowd Radio is becoming HealthTree Podcast for Multiple Myeloma
Jesus Berdeja, MD
Sarah Cannon Research Institute
Interview Date: June 27, 2022
CAR T therapy is both FDA approved and continues to be in development in clininical trials. While the Abecma and CARVYKTI products used commercially are autologous (meaning they use a patients' own T cells), a whole new set of CAR T products in developmnet are allogeneic, or "off-the-shelf." These allogeneic CAR T options could provide faster access, less bridging therapy and better availability. Learn more from CAR T myeloma expert Jesus Berdeja, MD about this class of new myeloma treatments in this important show.
Thanks to our episode sponsor

Dr. Jesus Berdeja

Jennifer Ahlstrom
